Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021-Reference-Cited by-同舟云学术

Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

Published:2021-03-25 Issue:12 Volume:26 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Subbarao Sathyavani¹^ORCID,Warrener Lenesha A²,Hoschler Katja²,Perry Keith R²,Shute Justin²,Whitaker Heather³,O’Brien Michelle⁴,Baawuah Frances⁴¹,Moss Paul⁵,Parry Helen⁵,Ladhani Shamez N⁶¹,Ramsay Mary E¹,Brown Kevin E¹,Amirthalingam Gayatri¹

Affiliation:

1. Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom

2. Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom

3. Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom

4. Brondesbury Medical Centre, Kilburn, London, United Kingdom

5. Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom

6. Paediatric Infectious Diseases Research Group, St. George’s University of London, London, United Kingdom

Abstract

Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference13 articles.

1. GOV.UK. Optimising the COVID-19 vaccination programme for maximum short-term impact. London: Department of Health and Social Care; 2021. Available from: https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement/optimising-the-covid-19-vaccination-programme-for-maximum-short-term-impact

2. Public Health England (PHE). Evaluation of the Abbott SARS-CoV-2 IgG for the detection of anti-SARS-CoV-2 antibodies. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890566/Evaluation_of_Abbott_SARS_CoV_2_IgG_PHE.pdf

3. Public Health England (PHE). Evaluation of Roche Elecsys AntiSARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies. London: PHE; 2020. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/891598/Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2_PHE_200610_v8.1_FINAL.pdf

4. Jeffery-Smith A, Dun-Campbell K, Janarthanan R, Fok J, Crawley-Boevey E, Vusirikala A, et al. Infection and transmission of SARS-CoV-2 in London care homes reporting no cases or outbreaks of COVID-19: prospective observational cohort study, England 2020. Lancet Regional Health - Europe. 2021;3:100038.

5. Imperial College. Real-time Assessment of Community Transmission (REACT) Study. London: Imperial College. [Accessed: Mar 2021]. Available from: https://www.reactstudy.org/

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of SARS-CoV-2 anti-Spike antibody levels and breakthrough infection risk among vaccinated adults in North Lebanon;PLOS ONE;2024-05-09

2. Applications of SARS-CoV-2 serological testing: impact of test performance, sample matrices, and patient characteristics;Critical Reviews in Clinical Laboratory Sciences;2023-10-06

3. Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod;Revue Neurologique;2023-03

4. The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection;Annals of Medicine;2023-02-23

5. Modeling the spatio‑temporal spread of COVID‑19 cases, recoveries and deaths and effects of partial and full vaccination coverage in Canada;Scientific Reports;2022-10-24